Market Outlook

Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is severely undertreated. The failure of therapies to improve walking distance or reduce amputation highlights the need for novel agents capable of reducing, preventing, or reversing the progression of PAD. We discuss how current therapies are differentiated based on their key attributes and measure the impact of these attributes on cardiologists’ prescribing behavior. We also discuss the most important unmet needs in the treatment of PAD and consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for PAD.

QUESTIONS ANSWERED

  • Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • Which PAD therapies are perceived by U.S. and European cardiologists as performing best on key treatment drivers and goals?
  • What are the major areas of opportunity for drug developers in PAD treatment and their likelihood of being fulfilled in the near future?
  • Based on the conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and price are acceptable to U.S. and European cardiologists for a hypothetical new PAD drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in June 2019.

Key drugs covered: Aspirin, clopidogrel, statins, Xarelto, Repatha, Praluent, and vasoactive agents.

Key metrics included Target Product Profile (TPP) simulator based on conjoint analysis methodology. Stated versus derived importance of product attributes on prescribing behavior. Assessment of current drug performance against treatment drivers and goals. Physician perceptions of unmet needs in the indication and related indications. Analysis of remaining drug development opportunities.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Detailed, Expanded Analysis (US & EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in PAD
      • Key Findings: Unmet Need in PAD and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Peripheral Arterial Disease Market and Emerging Therapy Insights
        • Opportunity: A Disease-Modifying Therapy
        • Opportunity: A Novel Agent Offering a Proven Reduction in Major Adverse Cardiovascular Events and All-Cause Mortality Rate
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • PAD Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Pallavi Malik, M.Sc

Pallavi Malik is a business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Biotechnology, and a Bachelor's degree in Science from the Panjab University, Chandigarh, India. Prior to joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve. Her role involved in-depth scientific secondary research, and competitive intelligence across multiple domains (such as oncology, ophthalmology and CVD) including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, competitor benchmarking, and opportunity assessment.  


Related Reports

Peripheral Arterial Disease | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key peripheral arterial di...

View Details

Peripheral Arterial Disease | Epidemiology | Epidemiology Dashboard

DRG Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological est...

View Details

Peripheral Arterial Disease | Current Treatment | Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is closely associated with coronary and cerebrovascular disease. Current treatment practic...

View Details

Peripheral Arterial Disease | Landscape and Forecast | Disease Landscape and Forecast

Market Outlook Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the art...

View Details